Non-alcoholic fatty liver. Nonalcoholic steatohepatitis (NASH)
Conditions
Interventions
Intervention 1: Intervention group: They will receive 240 mg tablets of Live Liver (Simorgh Pharmaceutical Company of Attar Drug and the country of manufacture of Iran) every 12 hours before meals wit
Sponsors
Islamic Azad University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Diagnosis of non-alcoholic fatty liver on ultrasound Diagnosis of non-alcoholic fatty liver by liver enzymes
Exclusion criteria
Exclusion criteria: Use of statins History of viral liver disease or chronic liver disease except fatty liver History of hepatitis (autoimmune and viral) Opioid users Dissatisfaction with participating in the study Patients with liver and bile duct cancers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alanine aminotransferase. Timepoint: The beginning of the intervention, two months after the intervention. Method of measurement: Biochemistry Laboratory.;Aspartate aminotransferase. Timepoint: The beginning of the intervention, two months after the intervention. Method of measurement: Biochemistry Laboratory.;Weight. Timepoint: The beginning of the intervention, two months after the intervention. Method of measurement: Digital balance. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSamira Kafshi
Islamic Azad University
Outcome results
None listed